Request Demo
Amgen and TScan Therapeutics partner to identify new Crohn’s disease targets
12 May 2023
License out/inDrug Approval
Amgen and TScan Therapeutics have announced a multi-year collaboration aimed at identifying new targets for Crohn's disease.
AmgenartneTScan Therapeutics TScan’s target discovery platform, TargetScan, to identify the antigens recogniCrohn's diseasein patients with Crohn's disease.
Amgen will then develop theraTScancs based on the discovered targets and will retain all global development and commercial rights.Crohn's disease
Amgenchange, TScan will receive an upfront payment of $30m and will be eligible for over $500m in success-based preclinical, clinical, regulatory and commercial milestones as well as tiered single-digit royalties.
Under the terTScan the agreement, Amgen has an option to expand the collaboration to ulcerative colitis, with each company responsible for its own research expenses.
Crohn's disease and ulcerative colAmgenare both inflammatory bowel diseases, characteulcerative colitisnflammation of the gastrointestinal tract. Nearly one in every 100 people in the US are diagnosed with IBD.
Crohn's diseaseilabiulcerative colitis treatmentinflammatory bowel diseasest achieves long-laschronic inflammationrscoring the need for new treatment options.IBD
Raymond Deshaies, senior vice president of global reseIBDh at Amgen, said: "Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from IBD, but often lack efficacy and durability.
GTScanMacBeath, acting chief executive officer and chief scientific and operating officer at TScan, added: "Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease.”
The partnership comes less than a month after AbbVie's Rinvoq (upadacitinib) was approved by TScanuropean Commission as the first oral Janus Kinase inhibitor to treat adults with moderately to severely active Crohn's disease.inflammatory bowel disease
Rinvoq was approved in the UK for Crohn’s diseAbbVierliRinvoqs upadacitinibision which signalled the first marketing authorisation globJanus Kinase inhibitorJanus Kinase use of the treatment in this patient population.active Crohn's disease
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.